Flector: Uses, Dosage & Side Effects

What Is Flector and What Is It Used For?

Flector contains the active substance diclofenac epolamine, which belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs). Diclofenac is one of the most widely studied and used analgesic and anti-inflammatory compounds in the world, with decades of clinical experience supporting its efficacy and safety profile. The epolamine salt form (also known as the hydroxyethylpyrrolidine salt) was specifically developed for topical use because it enhances the drug's ability to penetrate through the skin barrier and reach the underlying tissues where pain and inflammation originate.

The mechanism of action of diclofenac epolamine involves the non-selective inhibition of cyclooxygenase enzymes (COX-1 and COX-2). These enzymes are responsible for converting arachidonic acid into prostaglandins, which are lipid mediators that play a central role in the inflammatory response. Prostaglandins such as PGE2 and PGI2 sensitize peripheral nociceptors (pain-sensing nerve endings), promote vasodilation, increase vascular permeability, and attract inflammatory cells to the site of tissue injury. By blocking the production of these prostaglandins at the local level, diclofenac epolamine reduces pain, swelling, heat, and redness in the affected area.

What distinguishes Flector from oral diclofenac formulations is its route of administration. When applied as a topical patch, diclofenac is delivered directly to the tissues beneath the application site. Pharmacokinetic studies have demonstrated that systemic bioavailability following topical application is less than 10% compared to equivalent oral doses. This means that while the drug reaches therapeutic concentrations in the local tissues (muscle, fascia, synovium, and subcutaneous tissue), plasma levels remain substantially lower than those achieved with oral administration. This pharmacokinetic advantage translates directly into a reduced risk of the systemic side effects that are well-known complications of oral NSAID therapy, particularly gastrointestinal adverse events such as peptic ulcers, dyspepsia, and gastrointestinal bleeding.

Flector is indicated for the topical treatment of acute pain associated with minor strains, sprains, and contusions. These are among the most common injuries encountered in both clinical practice and daily life, affecting athletes, workers, and the general population alike. A strain refers to an injury to a muscle or the tendon that connects it to bone, typically caused by overstretching or excessive force. A sprain involves damage to a ligament, the tough band of connective tissue that connects bones across a joint. Contusions (bruises) result from a direct blow to the body that damages the underlying muscle fibers and connective tissue without breaking the skin. All three of these injury types involve an acute inflammatory response that produces pain, swelling, and limited range of motion.

Clinical evidence supporting the efficacy of topical diclofenac for acute musculoskeletal pain is robust. A landmark Cochrane systematic review analyzing data from multiple randomized controlled trials found that topical NSAIDs, including diclofenac formulations, are effective for treating acute soft tissue injuries, with a number needed to treat (NNT) of approximately 4 to 5 for achieving at least 50% pain relief over 7 days. This means that for every 4 to 5 patients treated with a topical NSAID, one additional patient achieves meaningful pain relief compared to placebo. The review concluded that topical NSAIDs provide a "good level of pain relief" for acute conditions without the systemic risks of oral formulations, and recommended them as a first-line option for localized musculoskeletal pain.

Flector was first approved by the FDA in the United States in 2007 and has since received marketing authorization in numerous countries across Europe, Asia, and Latin America. It is manufactured by IBSA Institut Biochimique SA, a Swiss pharmaceutical company that pioneered the development of the diclofenac epolamine patch technology. In many markets, Flector is available over the counter (OTC) for self-medication of minor musculoskeletal injuries, reflecting the favorable safety profile of this topical formulation. In some jurisdictions, certain indications or durations of use may require a prescription; patients should verify the regulatory status in their country.

What Should You Know Before Taking Flector?

Contraindications

Flector must not be used in the following circumstances. Firstly, it is contraindicated in individuals with a known hypersensitivity (allergy) to diclofenac, to the epolamine salt, or to any of the other ingredients in the patch formulation. Cross-sensitivity with other NSAIDs is possible, meaning that patients who have experienced allergic reactions to ibuprofen, naproxen, aspirin, or other NSAIDs should exercise caution and consult a healthcare provider before using Flector.

Secondly, Flector must not be used by patients in whom aspirin or other NSAIDs trigger asthma attacks, urticaria (hives), or acute rhinitis. This condition, known as aspirin-exacerbated respiratory disease (AERD) or Samter's triad, affects approximately 7% of adult asthma patients and is characterized by the triad of asthma, nasal polyps, and aspirin sensitivity. In these patients, even topical NSAID exposure can potentially trigger bronchospasm and severe respiratory symptoms.

Thirdly, Flector must not be applied to skin that is damaged, broken, or affected by dermatological conditions. This includes open wounds, cuts, abrasions, burns, eczema, psoriasis, and infected skin. Application to compromised skin can lead to increased systemic absorption, local irritation, and delayed wound healing. The patch should also not be applied to mucous membranes or used near the eyes.

Finally, Flector is contraindicated during the third trimester of pregnancy (from week 29 onwards) due to the risk of premature closure of the ductus arteriosus in the fetus and potential inhibition of uterine contractions. All NSAIDs, including topically applied formulations, carry this risk in late pregnancy.

Warnings and Precautions

Although Flector's topical application route results in much lower systemic drug levels compared to oral NSAIDs, certain precautions should be observed, particularly in patients with pre-existing medical conditions or those using concomitant medications. Before using Flector, discuss the following with your healthcare provider:

• Gastrointestinal history: Patients with a history of peptic ulcer disease, gastrointestinal bleeding, or inflammatory bowel disease (Crohn's disease, ulcerative colitis) should use Flector with caution. While topical application significantly reduces gastrointestinal risk compared to oral NSAIDs, some systemic absorption does occur and may theoretically affect the gastrointestinal tract in susceptible individuals.
• Cardiovascular disease: NSAIDs have been associated with an increased risk of cardiovascular thrombotic events, including myocardial infarction and stroke, particularly with prolonged use at high systemic doses. Although topical NSAIDs result in minimal systemic exposure, patients with established cardiovascular disease, heart failure, or significant cardiovascular risk factors should inform their doctor before using Flector for extended periods.
• Renal and hepatic impairment: Patients with significantly impaired kidney or liver function should consult a healthcare provider before using Flector. While systemic absorption is low, the residual amount of drug that enters the circulation is metabolized by the liver and excreted by the kidneys. Patients with severe renal or hepatic impairment may have altered drug clearance.
• Elderly patients: Older adults are at higher risk for adverse effects from NSAIDs, including gastrointestinal and renal complications. Elderly patients should use Flector with appropriate caution and should not exceed the recommended treatment duration without medical supervision.
• Sun exposure: The treated area should not be exposed to direct sunlight or UV light (including sunbeds) during treatment and for two weeks after removing the patch, as diclofenac can cause photosensitivity reactions.

Pregnancy and Breastfeeding

The use of Flector during pregnancy requires careful consideration depending on the trimester. During the first and second trimesters, Flector should only be used if clearly necessary and for the shortest duration possible, as the effects on early pregnancy have not been fully characterized in human studies. Animal studies with oral diclofenac at systemic doses far exceeding those achieved by topical application have shown some evidence of reproductive toxicity, including delayed parturition and increased peri-natal mortality. However, the relevance of these findings to the low systemic exposure from the topical patch is uncertain.

During the third trimester of pregnancy (from week 29), Flector is strictly contraindicated. All NSAIDs can cause premature closure of the ductus arteriosus in the fetal heart, which can lead to persistent pulmonary hypertension in the newborn. NSAIDs may also inhibit uterine contractions, potentially prolonging labor and increasing the risk of postpartum hemorrhage. Additionally, NSAIDs used in late pregnancy can impair fetal renal function, leading to oligohydramnios (reduced amniotic fluid).

For breastfeeding mothers, diclofenac is excreted in small amounts in breast milk. Given the low systemic absorption from topical application, the amount reaching breast milk after use of the Flector patch is expected to be very small. Nevertheless, as a precaution, breastfeeding mothers should consult their doctor before using Flector. If use is deemed necessary, the patch should not be applied to the breasts to avoid direct oral exposure to the infant.

Children and Adolescents

The safety and efficacy of Flector in children under 16 years of age have not been established in clinical trials. Therefore, use in this age group is generally not recommended unless directed by a healthcare provider. Adolescents aged 16 and older may use Flector in accordance with the adult dosing recommendations. Parents and caregivers should consult a pediatrician before applying Flector to children or adolescents for musculoskeletal injuries.

How Does Flector Interact with Other Drugs?

The topical route of administration of Flector means that systemic drug levels are substantially lower than those achieved with oral diclofenac formulations. As a result, the risk of clinically significant drug interactions is considerably reduced compared to oral NSAIDs. Nevertheless, because some systemic absorption does occur, it is prudent to be aware of potential interactions, particularly in patients using multiple medications or those with conditions that increase susceptibility to drug interactions.

Diclofenac, the active component of Flector, is metabolized primarily by hepatic cytochrome P450 enzymes, predominantly CYP2C9, with minor contributions from CYP3A4, CYP2C8, and UGT2B7 (glucuronidation). At the low systemic concentrations achieved with topical application, enzyme inhibition or induction effects are not expected to be clinically relevant. However, patients should inform their healthcare provider about all prescription and non-prescription medications they are taking.

Major Interactions

The most clinically relevant interaction to be aware of is the concurrent use of Flector with oral NSAIDs. Using a topical NSAID patch while also taking an oral NSAID such as ibuprofen, naproxen, or prescription-strength diclofenac results in additive NSAID exposure, which can increase the risk of gastrointestinal adverse events (ulcers, bleeding), renal impairment, and cardiovascular effects. Patients should generally not use Flector while taking oral NSAIDs unless specifically directed by a healthcare provider.

Patients taking anticoagulant medications such as warfarin, heparin, or direct oral anticoagulants (DOACs like rivaroxaban, apixaban, and dabigatran) should inform their doctor before using Flector. All NSAIDs have antiplatelet properties and can increase the risk of bleeding when combined with anticoagulants. Although the systemic NSAID levels from topical application are low, bleeding risk should still be monitored, particularly in patients with additional risk factors such as advanced age, concurrent antiplatelet therapy, or a history of bleeding events.

Minor Interactions

Interactions with lithium, methotrexate, ACE inhibitors, ARBs, and diuretics are well-documented for oral NSAIDs but are considered unlikely to be clinically significant with topical application due to the low systemic bioavailability of Flector. Nevertheless, patients taking these medications should be aware of the theoretical interactions and report any unusual symptoms to their healthcare provider. This is particularly relevant for patients using high-dose methotrexate for oncological or rheumatological conditions, where even small changes in methotrexate clearance can have clinically meaningful consequences.

There are no known interactions between Flector and food, alcohol, or herbal supplements at the low systemic doses achieved through topical application. However, alcohol consumption may independently increase the risk of gastrointestinal irritation and should be moderated during any NSAID use.

What Is the Correct Dosage of Flector?

Flector is designed for simple, twice-daily application. The recommended dosage is based on the standard patch formulation containing 180 mg of diclofenac epolamine (equivalent to 1.3% w/w) distributed uniformly across the adhesive matrix of the patch. The following dosage information applies to the standard Flector medicated plaster and may vary slightly depending on the specific product formulation available in your country.

Adults

How to Apply the Patch

Proper application technique is important for achieving optimal pain relief and minimizing skin reactions. Follow these steps each time you apply a new Flector patch:

1. Clean and dry the skin: Wash the affected area gently with soap and water, then pat it completely dry. Do not apply the patch to wet or damp skin, as this may affect adhesion.
2. Open the sachet carefully: Cut open the sealed sachet along the designated line. Remove the patch and peel off the protective release liner.
3. Apply the patch: Place the adhesive side of the patch directly over the most painful area. Press it firmly with the palm of your hand for approximately 10 seconds to ensure good contact with the skin.
4. Wash your hands: After applying the patch, wash your hands thoroughly to remove any residual medication, unless your hands are the area being treated.
5. Leave in place: Keep the patch on for up to 12 hours. Do not bathe, shower, or swim while wearing the patch, as water may loosen it.
6. Remove and replace: After 12 hours, gently peel off the used patch and apply a new one if needed. Allow a brief interval between patches to let the skin recover.

Missed Dose

If you forget to apply a new patch at the scheduled time, apply it as soon as you remember. If it is nearly time for your next scheduled application, skip the missed dose and continue with your regular schedule. Do not apply two patches simultaneously to make up for a missed application. Because Flector is used for symptomatic relief rather than to maintain steady-state drug levels, occasional missed applications will not significantly affect the overall treatment outcome.

Overdose

Overdose with Flector through topical application is unlikely due to the self-limiting nature of the patch formulation. Each patch contains a fixed amount of drug, and absorption through intact skin is controlled. However, if multiple patches are applied simultaneously or if the patch is accidentally ingested, the risk of systemic NSAID toxicity increases. Symptoms of NSAID overdose may include nausea, vomiting, epigastric pain, gastrointestinal bleeding, drowsiness, dizziness, headache, and in severe cases, renal impairment or metabolic acidosis.

In the event of accidental ingestion of the patch or suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is supportive and symptomatic, as there is no specific antidote for diclofenac overdose. Activated charcoal may be considered if the ingestion is recent and the patient is alert.

What Are the Side Effects of Flector?

Like all medicines, Flector can cause side effects, although not everybody gets them. The side effect profile of topical diclofenac is markedly different from that of oral formulations, reflecting the much lower systemic drug exposure achieved through transdermal delivery. The vast majority of adverse events reported with Flector are local skin reactions at or near the application site, which are generally mild to moderate in severity and resolve spontaneously after the patch is removed.

Clinical trials and post-marketing surveillance have characterized the following side effects according to standard frequency categories established by the Council for International Organizations of Medical Sciences (CIOMS) and adopted by the European Medicines Agency (EMA):

It is important to note that the gastrointestinal side effects that are the primary concern with oral NSAIDs (peptic ulcers, gastrointestinal bleeding, dyspepsia) are substantially less common with topical formulations like Flector. A Cochrane review comparing topical and oral NSAIDs found that the incidence of gastrointestinal adverse events with topical NSAIDs was similar to placebo and significantly lower than with oral formulations. This represents one of the key clinical advantages of the topical route of administration.

Cardiovascular adverse effects, which have been a focus of regulatory attention for oral NSAIDs, are also considered to be of minimal concern with topical application due to the low systemic exposure. Nevertheless, long-term use of any NSAID, including topical formulations, in patients with significant cardiovascular risk factors should be discussed with a healthcare provider.

How Should You Store Flector?

Proper storage is essential to maintaining the integrity and effectiveness of Flector patches. The medicated plaster is a complex pharmaceutical product that contains an adhesive matrix impregnated with diclofenac epolamine. Environmental factors such as temperature, humidity, and light exposure can affect the stability of the active ingredient, the adhesive properties of the patch, and the release characteristics of the formulation.

Flector patches should be stored in their original sealed sachets until immediately before use. Each sachet is designed to protect the patch from moisture, light, and air. Once removed from the sachet, the patch should be applied immediately. Do not store opened or partially used patches for later use, as the adhesive may degrade and the drug release properties may be altered.

The recommended storage temperature is below 25°C (77°F). The patches should not be refrigerated or frozen, as extreme cold can affect the adhesive matrix and drug distribution within the patch. Store the patches in a dry location away from direct sunlight and heat sources such as radiators or windowsills. Do not store patches in the bathroom, where humidity levels are typically high.

Keep Flector patches out of the reach and sight of children. Although topical application from a single patch is unlikely to cause serious harm in a child, accidental ingestion of the patch contents could potentially lead to systemic NSAID toxicity. Used patches should be folded in half with the adhesive side inward and disposed of properly, as they still contain residual amounts of active medication. Do not flush used patches down the toilet; instead, dispose of them in household waste, wrapped securely to prevent accidental contact by children or pets.

Check the expiration date printed on the sachet and outer packaging before each use. Do not use Flector patches after the expiry date. Expired patches may have reduced efficacy due to degradation of the active ingredient or deterioration of the adhesive system. If you have expired or unused patches that you no longer need, consult your pharmacist about proper disposal methods in accordance with local regulations.

What Does Flector Contain?

Understanding the complete composition of Flector is important for patients who may have allergies or sensitivities to specific ingredients. The patch is a multi-layered pharmaceutical product consisting of a drug-containing adhesive matrix layer, a non-woven backing fabric, and a protective release liner that is removed before application.

The active ingredient is diclofenac epolamine (also known as diclofenac hydroxyethylpyrrolidine), 180 mg per patch, equivalent to 1.3% w/w. Diclofenac epolamine is the epolamine (N-(2-hydroxyethyl)pyrrolidine) salt of diclofenac, a phenylacetic acid derivative. This salt form was specifically selected for the topical patch formulation because it confers superior skin permeation properties compared to the sodium salt used in oral formulations, enabling effective transdermal drug delivery without the need for chemical penetration enhancers.

The inactive ingredients (excipients) in the Flector patch typically include:

• Adhesive matrix: A self-adhesive polymer system that ensures the patch stays firmly attached to the skin for the full 12-hour application period. This typically includes acrylic adhesive copolymers and tackifying resins.
• Propylene glycol: Acts as a humectant and co-solvent that helps maintain the hydration of the adhesive matrix and facilitates drug release from the polymer into the skin.
• Titanium dioxide: A white pigment used in the backing layer that provides opacity and protects the drug-containing layer from light degradation.
• Non-woven fabric backing: The outer layer of the patch that provides structural support, flexibility, and comfort during wear. It is typically made from polyester or polypropylene fibers.
• Release liner: A siliconized polyester film that protects the adhesive surface and is removed immediately before application. This component is not part of the applied patch.
• Additional excipients: Depending on the specific product formulation, may include sorbitol, gelatin, povidone, kaolin, fragrance, and other processing aids. The exact excipient list may vary between different Flector product formulations marketed in different countries.

Patients with known allergies to any of the listed excipients should consult their pharmacist or doctor before using Flector. The patch is free from latex and does not contain any preservatives such as parabens. It is also free from natural rubber, which is relevant for patients with latex sensitivity.